Cargando…
FKBP11 improves the malignant property of osteosarcoma cells and acts as a prognostic factor of osteosarcoma
Background: Osteosarcoma has become the most common bone malignancy in adolescents. Although the clinical treatment of osteosarcoma has advanced considerably in recent years, the 5-year survival rate has not improved significantly. Recently, many studies have shown that mRNA has unique advantages as...
Autores principales: | Zeng, Duo, Li, Jiayu, Yuan, Xuhui, Cai, Feng, Yu, Bo, Liu, Lang, Chen, Qinchan, Zhang, FeiFei, Liang, Yiping, Tang, Xiaofeng, Peng, Yuanxiang, Qu, Gaoyang, Wu, Pengyun, Jiao, QuanHui, Sun, Longhua, Lv, Xiao-Bin, Liao, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120909/ https://www.ncbi.nlm.nih.gov/pubmed/37014329 http://dx.doi.org/10.18632/aging.204523 |
Ejemplares similares
-
LncRNA LBX2-AS1 impacts osteosarcoma sensitivity to JQ-1 by sequestering miR-597-3p away from BRD4
por: Li, Jiayu, et al.
Publicado: (2023) -
Indirect bilirubin impairs invasion of osteosarcoma cells via inhibiting the PI3K/AKT/MMP-2 signaling pathway by suppressing intracellular ROS
por: Yuan, Xuhui, et al.
Publicado: (2023) -
The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022) -
FKBP14 overexpression contributes to osteosarcoma carcinogenesis and indicates poor survival outcome
por: Huang, Zhongming, et al.
Publicado: (2016) -
HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU
por: Sun, Jun, et al.
Publicado: (2021)